FindTrial
Sign In

A Study on Predicting Hemostatic Efficacy of Tumor Radiotherapy Based on the Bleeding Surface Area/Volume Ratio (S/V)

A Study on Predicting Hemostatic Efficacy of Tumor Radiotherapy Based on the Bleeding Surface Area/Volume Ratio (S/V)

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2600119449
Enrollment
Unknown
Registered
2026-02-27
Start date
2026-03-01
Completion date
Unknown
Last updated
2026-03-02

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Tumor bleeding

Interventions

Good-response group and poor-response group:None

Sponsors

Southern Medical University Southern Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1.Voluntarily sign the informed consent form; 2.Age >= 18; 3.Gender: No restrictions; 4.Patients who received radiotherapy hemostasis treatment at Nanfang Hospital of Southern Medical University from January 2024 to January 2026; 5.The reason for hemostasis in radiotherapy is tumor bleeding (tumors include gastric cancer, intestinal cancer, cervical cancer, endometrial cancer, etc., and metastatic tumors are also included). 6.The hemostatic effect can be evaluated; 7.The baseline information and radiotherapy information are complete;

Exclusion criteria

Exclusion criteria: 1.Pregnant or lactating female patients; 2.Patients who were judged by the researchers as unsuitable to participate in this study;

Design outcomes

Primary

MeasureTime frame
Therapeutic effect of radiotherapy for hemostasis;—

Countries

China

Contacts

Public ContactZhang Yaowei

Southern Medical University Southern Hospital

weiyaozhang2@163.com+86 20 62786617

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Mar 14, 2026